

SEATTLE GENETICS INC /WA  
Form SC 13D/A  
September 15, 2016

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13D  
Under the Securities Exchange Act of 1934

(Amendment No. 22)

**Seattle Genetics,  
Inc.**

(Name of Issuer)

**Common Stock, par  
value \$0.001 per  
share**

(Title of Class of  
Securities)

**812578102**  
(CUSIP  
Number)

**Alexandra A.  
Toohey**

**Chief Financial  
Officer**

**Baker Bros.  
Advisors LP  
667 Madison  
Avenue, 21st Floor  
New York, NY  
10065**

**(212) 339-5690**  
(Name, Address and  
Telephone Number  
of Person Authorized  
to Receive Notices  
and  
Communications)

**N/A**

(Date of  
Event which  
Requires  
Filing of this  
Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. "

**Note:** Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 812578102 Page 2 of 16 Pages

NAMES OF REPORTING  
PERSONS

1

Baker Bros. Advisors LP

2

CHECK THE  
APPROPRIATE  
BOX IF A (a)

MEMBER OF A (b)  
GROUP (See

Instructions)

3

SEC USE ONLY

SOURCE OF FUNDS (See  
Instructions)

4

OO

5

CHECK BOX  
IF  
DISCLOSURE  
OF LEGAL  
PROCEEDINGS "

IS REQUIRED  
PURSUANT TO  
ITEMS 2(d) OR  
2(e)

CITIZENSHIP OR PLACE  
OF ORGANIZATION

6

Delaware

SOLE  
VOTING  
POWER

**7**

44,209,554 (1)

SHARED  
VOTING  
POWER

**8**

NUMBER OF  
SHARES  
BENEFICIALLY  
OWNED BY  
EACH  
REPORTING  
PERSON  
WITH

0

SOLE  
DISPOSITIVE  
POWER

**9**

44,209,554 (1)

SHARED  
DISPOSITIVE  
POWER

**10**

0

AGGREGATE AMOUNT  
BENEFICIALLY OWNED  
BY EACH REPORTING  
PERSON

**11**

44,209,554 (1)

**12**

CHECK BOX IF  
THE AGGREGATE  
AMOUNT IN ROW  
(11) EXCLUDES  
CERTAIN

SHARES (See  
Instructions)  
PERCENT OF CLASS  
REPRESENTED BY  
AMOUNT IN ROW (11)

**13**

31.4% (1)(2)

TYPE OF REPORTING  
PERSON (See Instructions)

**14**

IA, PN

(1) Includes 109,260 shares of the Issuer's common stock underlying 109,260 options.

(2) Based on 140,516,451 shares of common stock as of July 20, 2016 as reported in the Issuer's 10-Q filed with the SEC on July 26, 2016.

**SCHEDULE 13D**

**CUSIP No. 812578102 Page 3 of 16 Pages**

**NAMES OF REPORTING  
PERSONS**

**1** Baker Bros. Advisors (GP)  
LLC

**2** CHECK THE  
APPROPRIATE (a)  
BOX IF A  
MEMBER OF A (b)  
GROUP (See  
Instructions)

**3** SEC USE ONLY  
SOURCE OF FUNDS (See  
Instructions)

**4** OO

**5** CHECK BOX  
IF  
DISCLOSURE  
OF LEGAL  
PROCEEDINGS  
IS REQUIRED  
PURSUANT TO  
ITEMS 2(d) OR  
2(e)

**6** CITIZENSHIP OR PLACE  
OF ORGANIZATION

Delaware

SOLE  
VOTING  
POWER

**7**

44,209,554 (1)

SHARED  
VOTING  
POWER

**8**

**NUMBER OF  
SHARES  
BENEFICIALLY  
OWNED BY  
EACH  
REPORTING  
PERSON  
WITH**

0

SOLE  
DISPOSITIVE  
POWER

**9**

44,209,554 (1)

SHARED  
DISPOSITIVE  
POWER

**10**

0

AGGREGATE AMOUNT  
BENEFICIALLY OWNED  
BY EACH REPORTING  
PERSON

**11**

44,209,554 (1)

**12**

CHECK BOX IF  
THE AGGREGATE  
AMOUNT IN ROW  
(11) EXCLUDES

CERTAIN  
SHARES (See  
Instructions)  
PERCENT OF CLASS  
REPRESENTED BY  
AMOUNT IN ROW (11)

**13**

31.4% (1)(2)

TYPE OF REPORTING  
PERSON (See Instructions)

**14**

HC, OO

(1) Includes 109,260 shares of the Issuer's common stock underlying 109,260 options.

(2) Based on 140,516,451 shares of common stock as of July 20, 2016 as reported in the Issuer's 10-Q filed with the SEC on July 26, 2016.



SCHEDULE 13D

CUSIP No. 812578102 Page 4 of 16 Pages

NAMES OF REPORTING  
PERSONS

1

Julian C. Baker

2

CHECK THE  
APPROPRIATE  
BOX IF A (a)  
MEMBER OF A (b)  
GROUP (See  
Instructions)

3

SEC USE ONLY  
SOURCE OF FUNDS (See  
Instructions)

4

OO

5

CHECK BOX  
IF  
DISCLOSURE  
OF LEGAL  
PROCEEDINGS "  
IS REQUIRED  
PURSUANT TO  
ITEMS 2(d) OR  
2(e)  
CITIZENSHIP OR PLACE  
OF ORGANIZATION

6

United States

SOLE  
VOTING  
POWER

**7**

44,347,979(1)

SHARED  
VOTING  
POWER

**8**

**NUMBER OF  
SHARES  
BENEFICIALLY  
OWNED BY  
EACH  
REPORTING  
PERSON  
WITH**

0

SOLE  
DISPOSITIVE  
POWER

**9**

44,347,979 (1)

SHARED  
DISPOSITIVE  
POWER

**10**

0

AGGREGATE AMOUNT  
BENEFICIALLY OWNED  
BY EACH REPORTING  
PERSON

**11**

44,347,979 (1)

**12**

CHECK BOX IF  
THE AGGREGATE  
AMOUNT IN ROW  
(11) EXCLUDES  
CERTAIN

SHARES (See  
Instructions)  
PERCENT OF CLASS  
REPRESENTED BY  
AMOUNT IN ROW (11)

**13**

31.5% (1)(2)

TYPE OF REPORTING  
PERSON (See Instructions)

**14**

IN, HC

(1) Includes 109,260 shares of the Issuer's common stock underlying 109,260 options.

(2) Based on 140,516,451 shares of common stock as of July 20, 2016 as reported in the Issuer's 10-Q filed with the SEC on July 26, 2016.

**SCHEDULE 13D**

**CUSIP No. 812578102 Page 5 of 16 Pages**

**NAMES OF REPORTING  
PERSONS**

**1**

Felix J. Baker

**2**

CHECK THE  
APPROPRIATE  
BOX IF A (a)  
MEMBER OF A (b)  
GROUP (See  
Instructions)

**3**

SEC USE ONLY  
SOURCE OF FUNDS (See  
Instructions)

**4**

OO

**5**

CHECK BOX  
IF  
DISCLOSURE  
OF LEGAL  
PROCEEDINGS " "  
IS REQUIRED  
PURSUANT TO  
ITEMS 2(d) OR  
2(e)  
CITIZENSHIP OR PLACE  
OF ORGANIZATION

**6**

United States

SOLE  
VOTING  
POWER

**7**

44,347,986 (1)

SHARED  
VOTING  
POWER

**8**

NUMBER OF  
SHARES  
BENEFICIALLY  
OWNED BY  
EACH  
REPORTING  
PERSON  
WITH

0

SOLE  
DISPOSITIVE  
POWER

**9**

44,347,986 (1)

SHARED  
DISPOSITIVE  
POWER

**10**

0

AGGREGATE AMOUNT  
BENEFICIALLY OWNED  
BY EACH REPORTING  
PERSON

**11**

44,347,986 (1)

**12**

CHECK BOX IF  
THE AGGREGATE  
AMOUNT IN ROW  
(11) EXCLUDES  
CERTAIN

SHARES (See  
Instructions)  
PERCENT OF CLASS  
REPRESENTED BY  
AMOUNT IN ROW (11)

**13**

31.5% (1)(2)

TYPE OF REPORTING  
PERSON (See Instructions)

**14**

IN, HC

(1) Includes 109,260 shares of the Issuer's common stock underlying 109,260 options.

(2) Based on 140,516,451 shares of common stock as of July 20, 2016 as reported in the Issuer's 10-Q filed with the SEC on July 26, 2016.

SCHEDULE 13D

CUSIP No. 812578102 Page 6 of 16 Pages

NAMES OF REPORTING  
PERSONS

**1** FBB2, LLC

**2** CHECK THE  
APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)  
(a)  
(b)

**3** SEC USE ONLY  
SOURCE OF FUNDS (See Instructions)

**4** OO

**5** CHECK BOX  
IF  
DISCLOSURE  
OF LEGAL  
PROCEEDINGS  
IS REQUIRED  
PURSUANT TO  
ITEMS 2(d) OR  
2(e)

**6** CITIZENSHIP OR PLACE  
OF ORGANIZATION

Delaware

SOLE  
VOTING  
POWER

7

18,243

SHARED  
VOTING  
POWER

8

NUMBER OF  
SHARES  
BENEFICIALLY  
OWNED BY  
EACH  
REPORTING  
PERSON  
WITH

0

SOLE  
DISPOSITIVE  
POWER

9

18,243

SHARED  
DISPOSITIVE  
POWER

10

0

AGGREGATE AMOUNT  
BENEFICIALLY OWNED  
BY EACH REPORTING  
PERSON

11

18,243

12

CHECK BOX IF " " ☐  
THE AGGREGATE



AMOUNT IN ROW  
(11) EXCLUDES  
CERTAIN  
SHARES (See  
Instructions)  
PERCENT OF CLASS  
REPRESENTED BY  
AMOUNT IN ROW (11)

**13**

(1)

TYPE OF REPORTING  
PERSON (See Instructions)

**14**

OO

(1) The percentage of ownership is less than 0.1%, based on 140,516,451 shares of common stock as of July 20, 2016 as reported in the Issuer's 10-Q filed with the SEC on July 26, 2016.

SCHEDULE 13D

CUSIP No. 812578102 Page 7 of 16 Pages

NAMES OF REPORTING  
PERSONS

**1** FBB3 LLC

**2** CHECK THE  
APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)  
(a)  
(b)

**3** SEC USE ONLY  
SOURCE OF FUNDS (See Instructions)

**4** OO

**5** CHECK BOX  
IF DISCLOSURE  
OF LEGAL PROCEEDINGS IS REQUIRED  
PURSUANT TO ITEMS 2(d) OR 2(e)

**6** CITIZENSHIP OR PLACE  
OF ORGANIZATION

Delaware

SOLE  
VOTING  
POWER

7

12,678

SHARED  
VOTING  
POWER

8

NUMBER OF  
SHARES  
BENEFICIALLY  
OWNED BY  
EACH  
REPORTING  
PERSON  
WITH

0

SOLE  
DISPOSITIVE  
POWER

9

12,678

SHARED  
DISPOSITIVE  
POWER

10

0

AGGREGATE AMOUNT  
BENEFICIALLY OWNED  
BY EACH REPORTING  
PERSON

11

12,678

12

CHECK BOX IF " "   
THE AGGREGATE

AMOUNT IN ROW  
(11) EXCLUDES  
CERTAIN  
SHARES (See  
Instructions)  
PERCENT OF CLASS  
REPRESENTED BY  
AMOUNT IN ROW (11)

**13**

(1)

TYPE OF REPORTING  
PERSON (See Instructions)

**14**

OO

(1) The percentage of ownership is less than 0.1%, based on 140,516,451 shares of common stock as of July 20, 2016 as reported in the Issuer's 10-Q filed with the SEC on July 26, 2016.

Page 7 of 16

**Amendment No. 22 to Schedule 13D**

This Amendment No. 22 to Schedule 13D amends and supplements the statements on the previously filed Schedule 13D, as amended, filed by Baker Bros. Advisors LP (the “Adviser”), Baker Bros. Advisors (GP) LLC (the “Adviser GP”), Julian C. Baker, Felix J. Baker, FBB2, LLC (“FBB2”) and FBB3 LLC (“FBB3”). Except as supplemented herein, such statements, as heretofore amended and supplemented, remain in full force and effect. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Each capitalized term used but not defined herein has the meaning ascribed to such term in the Schedule 13D, as amended.

The Adviser GP is the sole general partner of the Adviser. Pursuant to management agreements, as amended, among the Adviser, Baker Brothers Life Sciences, L.P. (“Life Sciences”) and 667, L.P. (“667”, and together with Life Sciences, the “Funds”), and their respective general partners, the Adviser has complete and unlimited discretion and authority with respect to the Funds’ investments and voting power over investments.

**Item 3. Source and Amount of Funds or Other Consideration.**

Item 3 of Schedule 13D is supplemented and amended, as the case may be, as follows:

The disclosure regarding the purchases in Item 5(c) below is incorporated herein by reference.

**Item 4. Purpose of the Transaction.**

Item 4 of Schedule 13D is supplemented and superseded, as the case may be, as follows:

The Funds hold securities of Seattle Genetics, Inc. (the “Issuer”) for investment purposes. The Reporting Persons or their affiliates may purchase additional securities or dispose of securities in varying amounts and at varying times depending upon the Reporting Persons’ continuing assessments of pertinent factors, including the availability of shares of Common Stock or other securities for purchase at particular price levels, the business prospects of the Issuer, other business investment opportunities, economic conditions, stock market conditions, money market conditions, the attitudes and actions of the board of directors and management of the Issuer, the availability and nature of opportunities to dispose of shares in the Issuer and other plans and requirements of the particular entities. The

Reporting Persons may discuss items of mutual interest with the Issuer, which could include items in subparagraphs (a) through (j) of Schedule 13D.

Depending upon their assessments of the above factors, the Reporting Persons or their affiliates may change their present intentions as stated above and they may assess whether to make suggestions to the management of the Issuer regarding financing, and whether to acquire additional securities of the Issuer, including shares of Common Stock (by means of open market purchases, privately negotiated purchases, exercise of some or all of the Stock Options (as defined below), or otherwise) or to dispose of some or all of the securities of the Issuer, including shares of Common Stock, under their control.

Except as otherwise disclosed herein, at the present time, the Reporting Persons do not have any plans or proposals with respect to any extraordinary corporate transaction involving the Issuer including, without limitation, those matters described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.

Item 5. Interest in Securities of the Issuer.

(a) and (b) Items 7 through 11 and 13 of each of the cover pages of this Amendment No. 22 are incorporated herein by reference. Set forth below is the aggregate number and percentage of shares of Common Stock directly held, as of the date hereof, by each of the following based upon 140,516,451 shares of common stock as of July 20, 2016 as reported in the Issuer's 10-Q filed with the SEC on July 26, 2016. Such percentage figures were calculated in accordance with Rule 13d-3 under the Securities Exchange Act of 1934, as amended.

<u>Holder</u>	<u>Number of Shares</u>	<u>Percentage of Class Outstanding</u>
667, L.P.	4,671,498	3.3%
Baker Brothers Life Sciences, L.P.	39,388,096	28.0%

The Adviser GP, Felix J. Baker and Julian C. Baker as principals of the Adviser GP, and the Adviser may be deemed to be beneficial owners of securities of the Issuer directly held by the Funds, and may be deemed to have the power to vote or direct the vote of and the power to dispose or direct the disposition of such securities.

The Reporting Persons disclaim beneficial ownership of the securities held by each of the Funds, and this Amendment No. 22 shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 13(d) or for any other purpose, except to the extent that any such Reporting Persons actually exercises voting or dispositive power with respect to such securities.

Julian C. Baker and Felix J. Baker are also the sole managers of FBB2 and FBB3 and as such may be deemed to be beneficial owners of shares of Common Stock held by FBB2 and FBB3 and may be deemed to have the power to vote or direct the vote and dispose or direct the disposition of those shares.

Felix J. Baker is a Director of the Issuer. In connection with his service on the Issuer's Board, Felix J. Baker holds options to purchase Common Stock of the Issuer ("Stock Options"), Common Stock and restricted stock units payable solely in Common Stock of the Issuer ("Restricted Stock") as disclosed in previous amendments to this Schedule 13D.

Felix J. Baker serves on the Issuer's Board as a representative of the Funds. The policy of the Funds and the Adviser does not permit employees of the Adviser to receive compensation for serving as a Director of the Issuer. Therefore, Felix J. Baker has no pecuniary interest in the Stock Options, Common Stock or Restricted Stock. The Funds are instead entitled to the pecuniary interest in the Stock Options, Common Stock and Restricted Stock.





The Adviser has voting and investment power over the Stock Options, Common Stock underlying such Stock Options, Restricted Stock and Common Stock held by Felix Baker. The Adviser GP, and Felix J. Baker and Julian C. Baker as principals of the Adviser GP, may be deemed to have the power to vote or direct the vote of and the power to dispose or direct the disposition of the Stock Options, Common Stock underlying such Stock Options, Restricted Stock and Common Stock of the Issuer held by Felix J. Baker.

(c) The following transactions in the Issuer's Common Stock were effected by the Funds noted below during the sixty days preceding the filing of this statement using working capital of the applicable purchasing Fund. All purchase transactions were effected in the open market directly with a broker-dealer. Except as disclosed herein, none of the Reporting Persons or their affiliates has effected any other transactions in securities of the Issuer during the past 60 days.

Edgar Filing: SEATTLE GENETICS INC /WA - Form SC 13D/A

Name	Date	Number of Shares	Transaction	Price/Share	Footnotes
667, L.P.	9/6/2016	9,074	Purchase	45.8037	1
667, L.P.	9/6/2016	2,735	Purchase	44.9819	2
667, L.P.	9/6/2016	8,360	Purchase	46.1022	3
667, L.P.	9/6/2016	35,263	Purchase	45.3863	4
667, L.P.	9/6/2016	3,600	Purchase	45.1026	5
667, L.P.	9/6/2016	84,331	Purchase	46.1709	6
667, L.P.	9/7/2016	667	Purchase	48.2853	7
Baker Brothers Life Sciences, L.P.	9/7/2016	5,930	Purchase	48.2853	7
667, L.P.	9/7/2016	967	Purchase	48.4368	8
Baker Brothers Life Sciences, L.P.	9/7/2016	8,598	Purchase	48.4368	8
667, L.P.	9/7/2016	1,314	Purchase	48.1594	9
Baker Brothers Life Sciences, L.P.	9/7/2016	11,681	Purchase	48.1594	9
667, L.P.	9/7/2016	62	Purchase	47.2697	10
Baker Brothers Life Sciences, L.P.	9/7/2016	548	Purchase	47.2697	10
667, L.P.	9/7/2016	1,457	Purchase	48.9534	11
Baker Brothers Life Sciences, L.P.	9/7/2016	12,955	Purchase	48.9534	11
667, L.P.	9/7/2016	1,556	Purchase	48.6100	12
Baker Brothers Life Sciences, L.P.	9/7/2016	13,825	Purchase	48.6100	12
667, L.P.	9/8/2016	106	Purchase	49.1810	13
Baker Brothers Life Sciences, L.P.	9/8/2016	944	Purchase	49.1810	13
667, L.P.	9/8/2016	628	Purchase	49.4589	14
Baker Brothers Life Sciences, L.P.	9/8/2016	5,581	Purchase	49.4589	14
667, L.P.	9/8/2016	11,397	Purchase	50.0487	15
Baker Brothers Life Sciences, L.P.	9/8/2016	101,290	Purchase	50.0487	15
667, L.P.	9/8/2016	5,405	Purchase	50.1047	16
Baker Brothers Life Sciences, L.P.	9/8/2016	48,036	Purchase	50.1047	16
667, L.P.	9/8/2016	3,813	Purchase	50.4778	17
Baker Brothers Life Sciences, L.P.	9/8/2016	33,893	Purchase	50.4778	17
667, L.P.	9/9/2016	3,181	Purchase	50.5452	18
Baker Brothers Life Sciences, L.P.	9/9/2016	28,271	Purchase	50.5452	18
667, L.P.	9/9/2016	894	Purchase	51.0500	19
Baker Brothers Life Sciences, L.P.	9/9/2016	7,944	Purchase	51.0500	19
667, L.P.	9/9/2016	19,201	Purchase	50.3787	20
Baker Brothers Life Sciences, L.P.	9/9/2016	170,652	Purchase	50.3787	20
667, L.P.	9/9/2016	2,637	Purchase	50.3266	21
Baker Brothers Life Sciences, L.P.	9/9/2016	23,440	Purchase	50.3266	21
667, L.P.	9/12/2016	3,728	Purchase	51.2545	22
Baker Brothers Life Sciences, L.P.	9/12/2016	33,241	Purchase	51.2545	22
667, L.P.	9/12/2016	262	Purchase	50.4829	23
Baker Brothers Life Sciences, L.P.	9/12/2016	2,338	Purchase	50.4829	23
667, L.P.	9/12/2016	940	Purchase	50.9864	24
Baker Brothers Life Sciences, L.P.	9/12/2016	8,380	Purchase	50.9864	24
667, L.P.	9/12/2016	101	Purchase	49.8350	
Baker Brothers Life Sciences, L.P.	9/12/2016	899	Purchase	49.8350	
667, L.P.	9/13/2016	10	Purchase	50.0000	
Baker Brothers Life Sciences, L.P.	9/13/2016	90	Purchase	50.0000	

Edgar Filing: SEATTLE GENETICS INC /WA - Form SC 13D/A

667, L.P.	9/13/2016 2,388	Purchase	50.408225
Baker Brothers Life Sciences, L.P.	9/13/2016 21,290	Purchase	50.408225

Page 11 of 16

667, L.P.	9/13/2016	2,445	Purchase	50.421426
Baker Brothers Life Sciences, L.P.	9/13/2016	21,804	Purchase	50.421426
667, L.P.	9/13/2016	101	Purchase	50.637027
Baker Brothers Life Sciences, L.P.	9/13/2016	899	Purchase	50.637027
667, L.P.	9/13/2016	6,565	Purchase	51.405728
Baker Brothers Life Sciences, L.P.	9/13/2016	58,541	Purchase	51.405728
667, L.P.	9/13/2016	2,730	Purchase	51.545729
Baker Brothers Life Sciences, L.P.	9/13/2016	24,339	Purchase	51.545729

(1) The reported price is a weighted average price. These shares were traded in multiple transactions at a prices ranging from \$45.40 to \$46.00. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the “Staff”), upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(2) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$44.83 to \$45.00. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(3) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$46.02 to \$46.15. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(4) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$45.18 to \$46.15. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(5) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$45.00 to \$45.15. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(6) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$46.00 to \$46.25. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(7) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$48.21 to \$48.35. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(8) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$48.36 to \$49.10. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(9) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$47.57 to \$48.45. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(10) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$47.25 to \$47.27. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(11) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$48.83 to \$49.20. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(12) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$48.30 to \$49.00. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(13) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$49.18 to \$49.19. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(14) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$49.37 to \$49.50. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(15) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$49.51 to \$50.29. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(16) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$49.53 to \$50.25. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(17) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$50.46 to \$50.50. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(18) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$50.24 to \$50.90. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(19) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$51.05 to \$51.05. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(20) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$50.16 to \$50.75. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(21) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$50.17 to \$50.61. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(22) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$50.66 to \$51.60. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(23) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$50.42 to \$50.50. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.



(24) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$50.70 to \$51.33. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(25) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$50.15 to \$50.72. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(26) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$50.20 to \$50.64. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(27) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$50.56 to \$50.73. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(28) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$50.73 to \$51.72. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(29) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$50.99 to \$51.70. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(d) Certain securities of the Issuer are held directly by 667, a limited partnership the sole general partner of which is Baker Biotech Capital, L.P., a limited partnership the sole general partner of which is Baker Biotech Capital (GP), LLC. Julian C. Baker and Felix J. Baker are the controlling members of Baker Biotech Capital (GP), LLC.

Certain securities of the Issuer are held directly by Life Sciences, a limited partnership the sole general partner of which is Baker Brothers Life Sciences Capital, L.P., a limited partnership the sole general partner of which is Baker Brothers Life Sciences Capital (GP), LLC. Julian C. Baker and Felix J. Baker are the controlling members of Baker Brothers Life Sciences Capital (GP), LLC.

(e) Not applicable.

Page 15 of 16

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

September 15, 2016

**BAKER BROS.  
ADVISORS LP**

By: Baker Bros. Advisors  
(GP) LLC,  
its general partner

By: /s/ Scott L. Lessing  
Name: Scott L. Lessing  
Title: President

**BAKER BROS.  
ADVISORS (GP) LLC**

By: /s/ Scott L. Lessing  
Name: Scott L. Lessing  
Title: President

/s/ Julian C. Baker  
Julian C. Baker

/s/ Felix J. Baker  
Felix J. Baker

FBB2, LLC

By: /s/ Julian C. Baker  
Name: Julian C. Baker  
Title: Manager

FBB3 LLC

By: /s/ Julian C. Baker

Name: Julian C. Baker

Title: Manager

Page 16 of 16